HomeCompareGBT vs SPHD

GBT vs SPHD: Dividend Comparison 2026

GBT yields 2.92% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHD wins by $2.4K in total portfolio value
10 years
GBT
GBT
● Live price
2.92%
Share price
$68.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.1K
Annual income
$352.49
Full GBT calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — GBT vs SPHD

📍 SPHD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBTSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBT + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBT pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBT
Annual income on $10K today (after 15% tax)
$248.21/yr
After 10yr DRIP, annual income (after tax)
$299.62/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, SPHD beats the other by $186.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBT + SPHD for your $10,000?

GBT: 50%SPHD: 50%
100% SPHD50/50100% GBT
Portfolio after 10yr
$25.3K
Annual income
$461.90/yr
Blended yield
1.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBT right now

GBT
Analyst Ratings
18
Buy
11
Hold
Consensus: Buy
Price Target
$60.38
-11.8% upside vs current
Range: $36.00 — $110.00
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBT buys
0
SPHD buys
0
No recent congressional trades found for GBT or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBTSPHD
Forward yield2.92%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$24.1K$26.5K
Annual income after 10y$352.49$571.32
Total dividends collected$3.2K$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: GBT vs SPHD ($10,000, DRIP)

YearGBT PortfolioGBT Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$10,992$292.01$11,133$432.85$141.00SPHD
2$12,061$299.98$12,363$450.36$302.00SPHD
3$13,213$307.63$13,695$467.39$482.00SPHD
4$14,453$314.97$15,138$483.90$685.00SPHD
5$15,787$321.98$16,697$499.88$910.00SPHD
6$17,221$328.69$18,382$515.31$1.2KSPHD
7$18,761$335.08$20,198$530.17$1.4KSPHD
8$20,416$341.18$22,157$544.46$1.7KSPHD
9$22,192$346.98$24,266$558.18$2.1KSPHD
10$24,098$352.49$26,536$571.32$2.4KSPHD

GBT vs SPHD: Complete Analysis 2026

GBTStock

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Full GBT Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this GBT vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBT vs SCHDGBT vs JEPIGBT vs OGBT vs KOGBT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.